Medicare Benefits Schedule - Note TN.1.12

Search Results for Note TN.1.12

View Related Items

Category 3 - THERAPEUTIC PROCEDURES

TN.1.12

Cytotoxic Chemotherapy Administration - (Item 13950)

Following a recommendation of a National Health and Medical Research Council review committee in 2005, Medicare benefits are no longer payable for professional services rendered for the purpose of administering microwave (UHF radiowave) cancer therapy, including the intravenous injection of drugs used in the therapy.

 

Related Items: 13950


Related Items

Category 3 - THERAPEUTIC PROCEDURES

13950

13950 - Additional Information

Item Start Date:
01-Nov-2020
Description Updated:
01-Nov-2020
Schedule Fee Updated:
01-Jul-2021

Parenteral administration of one or more antineoplastic agents, including agents used in cytotoxic chemotherapy or monoclonal antibody therapy but not agents used in anti-resorptive bone therapy or hormonal therapy, by or on behalf of a specialist or consultant physician—attendance for one or more episodes of administration

Note: The fee for item 13950 contains a component which covers the accessing of a long-term drug delivery device. TN.1.27 refers

Fee: $112.40 Benefit: 75% = $84.30 85% = $95.55

(See para TN.1.12, TN.1.27 of explanatory notes to this Category)


Legend

  • Assist - Addition/Deletion of (Assist.)
  • Amend - Amended Description
  • Anaes - Anaesthetic Values Amended
  • Emsn - EMSN Change
  • Fee - Fee Amended
  • Renum - Item Number Change (renumbered)
  • New - New Item
  • NewMin - New Item (previous Ministerial Determination)
  • Qfe - QFE Change